cagrilintide semaglutide peptide Cagrilintide, (Blend) Cagrilintide 10mg, Semaglutide 10mg Blend

Oral semaglutide in PIONEER-6 (2019) confirmed non-inferiority for MACE (HR 0.79, 95% CI 0.571.11) but shone in mortality outcomes, cutting CV death by 51% (HR 0.49, 95% CI 0.270.92) and all-cause death by 49% (HR 0.51, 95% CI 0.310.84), validating the convenience of oral delivery [49]

The starting dose is 1.5 mg, which can increase to a maintenance dose of 25 mg

Aliment Pharmacol Ther 37:234242 Petit JM, Cercueil JP, Loffroy R et al (2017) Effect of Liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study

doi: 10.1016/S0140-6736(21)01324-6 [DOI] [PubMed] [Google Scholar] 191.Fras JP, Davies MJ, Rosenstock J, et al